Lipitor keeps on selling, so Pfizer will keep on producing it in Ireland

It's official: Demand for the off-patent drug Lipitor has inspired Pfizer ($PFE) to keep an Irish plant it had slated for closure. Sales in emerging markets, and to a lesser extent the U.S., are behind the change of mind, which saves 160 jobs in Little Island, Cork. Improved productivity at the plant helped, too. Release | More

Suggested Articles

Rather than accept a filing based on phase 1/2 data, the FDA wants Novartis to run a phase 3 for a market-expanding version of gene therapy Zolgensma.

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Call it a fall sports bounce. TV ad spending bumped up in August with the partial return of professional sports, and that included pharma buyers.